摘要
p53基因是目前细胞抑癌基因中研究最为广泛和深入的基因之一，它可以通过转录依赖或转录非依赖途径诱导细胞凋亡现象的发生。而骨肉瘤是一种常见的骨原发恶性肿瘤，其发病年龄多在11-30岁，严重危害青少年的身体健康。众多研究表明p53基因参与了骨肉瘤的发生、发展过程，并影响着骨肉瘤的治疗效果与预后。随着分子生物学手段的不断发展和完善，p53基因治疗将在骨肉瘤的治疗中体现出不可估量的作用。本文将就p53基因在骨肉瘤中的研究进展作一综述。
出处
《中国伤残医学》
2013年第12期375-376,共2页
Chinese Journal of Trauma and Disability Medicine
基金
山西省长治市科技创新计划项目(0900036)
参考文献18
-
1吴强,杨述华.p53基因在骨肉瘤中的研究进展[J].国外医学（骨科学分册）,2002,23(4):226-229. 被引量：2
-
2张立智,蔡宣松.P53基因治疗在骨肉瘤中的应用及展望[J].同济大学学报（医学版）,2002,23(5):435-437. 被引量：3
-
3Guo W, Wang X, Feng C. p53 gene abnormalities in osteosarcoma. [J].Chin Med J(Engl), 1996,109(10) :752-755.
-
4Toguchida J, Yamaguchi T, Hitchie B, eta[. Mutation spectrum ot the p53 gene in bone and soft tissue sarcomas. [J].Cancer Res, 1992,52(22) :6194-6199.
-
5Lopes MA, Nikitakis NG, Ord RA, et al. Amplification and protein expression of chromosome 12q 13-15 genes in osteosarcomas of the jaws. [J].Oral Oncol,2001,37(7) :566-571.
-
6Lonardo F, Ueda T, Huvos AG, et al. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and prohferative rate. [J].Cancer, 1997,79 (8) - 1541 - 1547.
-
7Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. [J].J Cancer Res Clin Oncol, 1996, 122(9) : 559-565.
-
8Wang H, Zeng X, Oliver P, et al. MDM2 oncogene as a target for cancer therapy: An antisense approach. [J]. |nt J Oncol, 1999, 15 (4) : 653-660.
-
9Nishikawa T, Yamamoto T, Mizuno K, et al. Expression of the p53 protein in human osteosareoma. [J].Nippon Seikeigeka Gakkai Zasshi, 1994,68(5) 400-406.
-
10Wadayama B, Toguchida J, Yamaguchi T, et al. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. [J].Br J Cancer, 1993,68(6) : 1134-1139.
二级参考文献39
-
1[1]Gokgoz N, Wnnder JS, Mousses S, et al. Comparision of P53 mutations in patients with localized osteosarooma and metastatic osteosarcoma[J]. Cancer, 2001,92(8):2181-2191.
-
2[2]Hasegawa T, Hirose T, Seki K, et al. Histological and immunohistochemical diversities and proliferative activity and grading in osteosarcomas[J]. Cancer Detect Prev,1997, 21(3):280-287.
-
3[3]Park YB, Kim HS, Oh JH, et al. The co-expression of P53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma[J ]. Int Orthop, 2001,24(6):307-310.
-
4[4]Goto A, Kanda H, Ishikawa Y, et al. Association of loss of heterozygosity at the P53 locus with chemoresistance in osteosarcomas[J].Jpn J Cancer Res, 1998, 89(5):539-547.
-
5[5]Asada N, Tsuchiya H, Tomita K. De novo deletions of P53 gene and wild-type P53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line[J].Anticancer Res, 1999, 19(6B) :5131 - 5137.
-
6[6]Wang LH, Okaichi K, Ihara M, et al. Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant P53 varied with mutation point[J]. Anticancer Res, 1998, 18(1A):321-325.
-
7[7]Wang JL, Sun Y, Wu S. Gamma-irradiation induces matrix metalloproteinase Ⅱ expression in a P53-dependent manner[J]. MolCarcinog, 2000, 27(4):252-258.
-
8[8]Sato N, Mizumoto K, Maehara N, et al. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1[J]. Anticancer Res, 2000, 20(2A) :837- 842.
-
9[9]Lin J, Jin X, Page C, et al. A modified P53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent[J]. Cancer Res, 2000, 60:5895-5901.
-
10[10]Bougeret C, Virone Oddos A, Adeline E, et al. Cancer gene therapy mediated by CTS1, a P53 derivative: advantage over wild-type P53 in growth inhibition of human tumors overexpressing MDM2[J]. Cancer Gene Ther, 2000 ;7(5) :789- 798.
共引文献3
-
1熊健,陈廖斌,鲁厚庚,余远举,许永涛.干扰素应答因子1对不同p53状态骨肉瘤凋亡的调节作用[J].中华实验外科杂志,2014,31(4):835-837. 被引量：1
-
2陈楷,吕书军,付东,李国东,蔡郑东.骨肉瘤凋亡与耐药相关机制的研究进展[J].中国骨与关节杂志,2015,4(1):45-49. 被引量：10
-
3陈杨,王世雯,艾克拜尔·尤努斯.TP53基因异常在骨肉瘤中的研究进展[J].临床医学进展,2023,13(3):3690-3696.
同被引文献7
-
1CHEN WQ,ZHENG RS, BAADE PD,et al.Cancer statistics in China,2015 [J/OL].CA Cancer J Clin, 2016(2016-1-25)[-2016- 1-311. http://onlinelibrary, wiley, com/doi/10. 3322/caac. 21338/ pdf.
-
2BLOT WJ, TARONE RE.Doll and Peto's quantitative estimates of cancer risks: holding generally true for 35 years [J/OL].J Natl Cancer Inst, 2015, 107 (4).. djv044 (doi: 10. 1093/jnci/ djv044).
-
3U.S.NATIONAL LIBRARY OF MEDICINE.Toxnet(Toxicolo- gy Data Network) [DB/OL].NLM (2015-1-20) [2015-1-20].http://toxnet.nlm.nih.gov/.
-
4INTERNATIONAL AGENCY FOR RESEARCH ON CANC- ER. Agents Classified by the IARC Monographs I-G/OLd. IARC, 2015.10 : 1-114 ( 2015-10-26 ) [ 2016-2-17. http://mono- graphs.iarc.fr/ENG/Classification/.
-
5ALBERTINI S,CHETELAT A,MILLER B, et al.Genotoxicity of 17 gyrase and four mammalian topoisomerase ll-Poisons in prokaryotic and eukaryotie test systems [J].Mutagenesis, 1995, 10(4) : 343-351.
-
6蔡柳洪,周灿权,张滨.荧光素酶标记转基因人胚胎干细胞的活体观察[J].中山大学学报（医学科学版）,2009,30(2):174-178. 被引量：6
-
7田云鹏,赵鹏伟,任明姬.P53基因与肿瘤的研究进展[J].疾病监测与控制,2013,7(12):740-741. 被引量：4
-
1刘赫,姜玉新,孟华,戴晴,齐振红.转移性乳腺癌的超声表现[J].中国介入影像与治疗学,2014,11(5):283-285. 被引量：2
-
2张伟.骨转移瘤影像诊断认识[J].医用放射技术杂志,2006(2):110-110.
-
3王保茎,秦全波,毛怡盛,孙晓民,赵平,孔玲,丁丹卉,常会超.磁共振扩散加权成像在肝脏恶性肿瘤诊断中的价值[J].中国临床研究,2013,26(10):1089-1090. 被引量：3
-
4熊茂婧,毕小琴.34例重组人腺病毒P53基因治疗颌面部恶性肿瘤的护理[J].当代护士（下旬刊）,2012,19(7):90-91.
-
5苟菊香,林小燕.p53基因治疗联合手术治疗晚期甲状腺癌病人的临床观察及护理[J].护士进修杂志,2013,28(13):1179-1180. 被引量：8
-
6张春明,蔡香然.单发脑实质内转移瘤的MRI诊断[J].实用医学影像杂志,1998(4):12-15.
-
7王娟,周健,李珍,韩利杰,桂瑞瑞,张龑莉,宋永平.治疗相关急性髓系白血病异基因造血干细胞移植后第一肿瘤复发一例报告并文献复习[J].中华血液学杂志,2015,36(11):960-962. 被引量：2
-
8李丹鸿,张晶,赵丽青.卵巢原发恶性肿瘤CT检查的价值[J].药物与人,2014,27(9):33-34.
-
9袁忠爱.磁共振弥散加权成像在恶性肿瘤诊断中的应用价值[J].医药前沿,2016,0(17):89-91. 被引量：1
-
10王锡臻,王滨,董鹏.前列腺癌影像学研究的生物学基础[J].中国临床医学影像杂志,2006,17(5):285-287.
